Asiatic acid attenuates CCl 4 -induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is a major pathological feature of chronic liver diseases, and effective therapies are limited at present. Asiatic acid (AA) is a triterpenoid isolated from Centella asiatica, which exhibits efficient anti‐inflammatory and anti‐oxidative activities. In this study, we attempted to evaluate the potential therapeutic effect of AA on CCl4‐induced liver fibrosis in rats and to investigate the underlying molecular mechanisms. Liver fibrosis‐related indexes including body weight, biochemical parameters, histological changes, the mRNA expression levels of inflammatory cytokines and biomarkers, and changes in the expression of related proteins in liver tissue were assessed. The results showed that AA treatment effectively ameliorated CCl4‐induced liver injury and fibrosis. Mechanistically, AA treatment attenuated CCl4‐induced oxidative stress, inflammation, and hepatocyte apoptosis and regulated the Bcl‐2/Bax signaling pathway in the liver. Additionally, we demonstrated that AA also inhibited hepatic stellate cell activation and extra cellular matrix (ECM) synthesis by regulating the PI3K/AKT/mTOR signaling pathway. In conclusion, these findings suggest that AA prevents the progression of liver fibrosis through multiple mechanisms and indicate that AA might be used for the treatment of liver fibrosis in the future. HIGHLIGHTSAsiatic acid (AA) attenuated CCl4‐induced liver injury and fibrosis in rats.AA mitigated oxidative stress and inflammation in CCl4‐induced liver fibrosis.AA regulated Bcl‐2/Bax signaling pathway to inhibit CCl4‐induced apoptosis.AA inhibited PI3K/AKT/mTOR signaling pathway to inhibit hepatic stellate cell activation and ECM synthesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
Decoding cell death signals in liver inflammation
Brenner, C., Galluzzi, L., Kepp, O., & Kroemer, G. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.033 · Cited by 1,022
Hepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Origin of myofibroblasts in the fibrotic liver in mice
Iwaisako, K., Jiang, C., Zhang, M., Cong, M., Moore-Morris, T. J., Park, T. J., Liu, X., Xu, J., Wang, P., Paik, Y.-H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400062111 · Cited by 535
Mesenchymal stem cell therapy for liver fibrosis
Eom, Y. W., Shim, K. Y., & Baik, S. K. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.5.580 · Cited by 226
Cited by
Therapeutic Potential of Centella asiatica and Its Triterpenes: A Review
Sun, B., Wu, L., Wu, Y., Zhang, C., Qin, L., Hayashi, M., Kudo, M., Gao, M., & Liu, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.568032 · Cited by 353
Phytobioactive compounds as therapeutic agents for human diseases: A review
Riaz, M., Khalid, R., Afzal, M., Anjum, F., Fatima, H., Zia, S., Rasool, G., Egbuna, C., Mtewa, A. G., Uche, C. Z., et al. (2023) · Food Science & Nutrition · doi:10.1002/fsn3.3308 · Cited by 355
Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics
Dolivo, D., Weathers, P., & Dominko, T. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.001 · Cited by 132
Pharmacological Effects of Centella asiatica on Skin Diseases: Evidence and Possible Mechanisms
Park, K. S. (2021) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2021/5462633 · Cited by 79
Tan, S. C., Bhattamisra, S. K., Chellappan, D. K., & Candasamy, M. (2021) · Applied Sciences · doi:10.3390/app11188475 · Cited by 72
Metadata
- Authors
- Wei, L., Chen, Q., Guo, A., Fan, J., Wang, R., & Zhang, H.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 60
- Pages
- 1-8
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W2801430251
- Cited by
- 106
- References
- 10
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Asiatic acid attenuates CCl 4 -induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways. https://app.cochat.ai/papers/10.1016/j.intimp.2018.04.016
- The paper
- Wei, L., Chen, Q., Guo, A., Fan, J., Wang, R., & Zhang, H. (2018). Asiatic acid attenuates CCl 4 -induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2018.04.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.